Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 2Phase NA 1Phase 3 1

Status

Unknown 2Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 1Carcinoma, Neuroendocrine 1

Interventions

Cisplatin 20Docetaxel 19Capecitabine 19Oxaliplatin 14Drug Therapy 14Cyclophosphamide 14Paclitaxel 13Fluorouracil 12Radiotherapy 11apatinib 9Gemcitabine 9Doxorubicin 9Decitabine 9Methotrexate 8Epirubicin 8Carboplatin 8sintilimab 6Etoposide 6camrelizumab 5anlotinib 5XELOX 5Sorafenib 5Radiation 5Pemetrexed 5Neoadjuvant Therapy 5Leucovorin 5Idarubicin 5Dexamethasone 5Cytarabine 5Busulfan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Unknown × EC regimen × Clear all
NCT04254471 2020-02-05

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Haihe Biopharma Co., Ltd.

Phase 2/3 Unknown
313 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT03992911 2019-06-20

Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma

Peking University

Phase 2/3 Unknown
336 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡